These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22849846)

  • 61. Icodextrin allergy in a peritoneal dialysis patient.
    Fletcher S; Stables GA; Turney JH
    Nephrol Dial Transplant; 1998 Oct; 13(10):2656-8. PubMed ID: 9794582
    [No Abstract]   [Full Text] [Related]  

  • 62. Advanced glycation end-products and skin autofluorescence in end-stage renal disease: a review.
    Arsov S; Graaff R; van Oeveren W; Stegmayr B; Sikole A; Rakhorst G; Smit AJ
    Clin Chem Lab Med; 2014 Jan; 52(1):11-20. PubMed ID: 23612551
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Systemic and local impact of glucose and glucose degradation products in peritoneal dialysis solution.
    Kim YL; Cho JH; Choi JY; Kim CD; Park SH
    J Ren Nutr; 2013 May; 23(3):218-22. PubMed ID: 23510669
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Biocompatibility of peritoneal dialysis fluid and influence of compositions on peritoneal fibrosis.
    Higuchi C; Nishimura H; Sanaka T
    Ther Apher Dial; 2006 Aug; 10(4):372-9. PubMed ID: 16911191
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Exposure to the peptidoglycan contaminant in icodextrin may cause sensitization of the patient maintained on peritoneal dialysis.
    Povlsen JV; Ivarsen P; Jørgensen KA; Madsen S
    Perit Dial Int; 2003; 23(5):509-10. PubMed ID: 14604210
    [No Abstract]   [Full Text] [Related]  

  • 66. Icodextrin is Associated with a Lower Risk of Stroke in Peritoneal Dialysis Patients.
    Chiu CW; Tsai TH; Lin CL; Yen TH; Wang IK; Li CY
    Nephron; 2019; 141(2):112-118. PubMed ID: 30423579
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Predictors of a favourable response to icodextrin in peritoneal dialysis patients with ultrafiltration failure.
    Wiggins KJ; Rumpsfeld M; Blizzard S; Johnson DW
    Nephrology (Carlton); 2005 Feb; 10(1):33-6. PubMed ID: 15705179
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effects of icodextrin on patient survival and technique success in patients undergoing peritoneal dialysis.
    Han SH; Ahn SV; Yun JY; Tranaeus A; Han DS
    Nephrol Dial Transplant; 2012 May; 27(5):2044-50. PubMed ID: 21968011
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Advanced glycation end products, measured as skin autofluorescence, at diagnosis in gestational diabetes mellitus compared with normal pregnancy.
    de Ranitz-Greven WL; Bos DC; Poucki WK; Visser GH; Beulens JW; Biesma DH; de Valk HW
    Diabetes Technol Ther; 2012 Jan; 14(1):43-9. PubMed ID: 21875328
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Masked hypoglycemia in the presence of icodextrin for peritoneal dialysis.
    Khouli MM
    J Emerg Med; 2013 Feb; 44(2):e191-3. PubMed ID: 22579020
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Inflammation and peritoneal dialysis fluids.
    Donovan KL
    Perit Dial Int; 2007; 27(1):98-9. PubMed ID: 17179522
    [No Abstract]   [Full Text] [Related]  

  • 72. Peritoneal dialysis in diabetic patients.
    Lee HB; Chung SH; Chu WS; Kim JK; Ha H
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S200-3. PubMed ID: 11576955
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Recurrent pancreatitis in an icodextrin-based peritoneal dialysis patient. Yet another case report.
    Hayat A; Thaneeru P; Priest P; Wilson R
    N Z Med J; 2013 Jun; 126(1377):67-9. PubMed ID: 23831880
    [No Abstract]   [Full Text] [Related]  

  • 74. Evaluation of advanced glycation end products accumulation, using skin autofluorescence, in CKD and dialysis patients.
    Oleniuc M; Schiller A; Secara I; Onofriescu M; Hogas S; Apetrii M; Siriopol D; Covic A
    Int Urol Nephrol; 2012 Oct; 44(5):1441-9. PubMed ID: 22160646
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3.
    McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW
    Clin J Am Soc Nephrol; 2011 Oct; 6(10):2356-63. PubMed ID: 21885790
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Icodextrin eliminates phosphate and ameliorates cardiac hypertrophy and valvular calcification in patients with end-stage renal disease and diabetes mellitus undergoing peritoneal dialysis.
    Hiramatsu T; Hayasaki T; Hobo A; Furuta S; Kabu K; Tonozuka Y; Iida Y
    Adv Perit Dial; 2013; 29():9-13. PubMed ID: 24344483
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Tissue-advanced glycation end product concentration in dialysis patients.
    McIntyre NJ; Chesterton LJ; John SG; Jefferies HJ; Burton JO; Taal MW; Fluck RJ; McIntyre CW
    Clin J Am Soc Nephrol; 2010 Jan; 5(1):51-5. PubMed ID: 19965551
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Skin autofluorescence: an emerging biomarker in persons with kidney disease.
    Viramontes Hörner D; Taal MW
    Curr Opin Nephrol Hypertens; 2019 Nov; 28(6):507-512. PubMed ID: 31589190
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tissue level of advanced glycation end products is an independent determinant of high-sensitivity C-reactive protein levels in haemodialysis patients.
    Nagano M; Fukami K; Yamagishi S; Sakai K; Kaida Y; Matsumoto T; Hazama T; Tanaka M; Ueda S; Okuda S
    Nephrology (Carlton); 2011 Mar; 16(3):299-303. PubMed ID: 21054666
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Association of advanced glycation end products, evaluated by skin autofluorescence, with lifestyle habits in a general Japanese population.
    Isami F; West BJ; Nakajima S; Yamagishi SI
    J Int Med Res; 2018 Mar; 46(3):1043-1051. PubMed ID: 29322837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.